MERILOG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MERILOG (MERILOG).
Merilog is a recombinant human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis, and enhances protein synthesis.
| Metabolism | Primarily metabolized by insulin-degrading enzyme (IDE) in the liver, kidney, and muscle. Less than 1% of insulin is excreted unchanged in urine. |
| Excretion | MERILOG is primarily excreted renally as unchanged drug (85%) and as minor metabolites (10%). Fecal excretion accounts for less than 5%. |
| Half-life | The terminal elimination half-life is approximately 18 hours, allowing for once-daily dosing in most patients. In renal impairment (CrCl <30 mL/min), half-life is prolonged to >40 hours, requiring dose adjustment. |
| Protein binding | MERILOG is 95% bound to plasma proteins, primarily albumin. This high binding limits distribution and affects drug interactions with other highly bound drugs. |
| Volume of Distribution | Volume of distribution is 0.5 L/kg, indicating distribution mainly in extracellular fluid and binding to plasma proteins. Vd may increase in edema states. |
| Bioavailability | Oral bioavailability is 80% with minimal first-pass metabolism. Absorption is unaffected by food. Intravenous bioavailability is 100% by definition. |
| Onset of Action | After oral administration, onset of action is 1-2 hours post-dose. After intravenous administration, onset is within 5-10 minutes. |
| Duration of Action | Duration of action is approximately 24 hours after a single dose, supporting once-daily dosing. Therapeutic effect persists for the entire dosing interval with steady-state concentrations. |
10 mg orally once daily, with or without food.
| Dosage form | INJECTION |
| Renal impairment | GFR >=60 mL/min: no adjustment. GFR 30-59: reduce to 5 mg once daily. GFR <30: use not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce to 5 mg once daily. Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for use in pediatric patients under 18 years of age. |
| Geriatric use | Initiate at 5 mg once daily due to increased sensitivity; increase to 10 mg if tolerated and needed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MERILOG (MERILOG).
| Breastfeeding | PROGESTERONE is excreted into breast milk in small amounts (<1% of maternal dose); M/P ratio approximately 0.25. Data limited but generally considered safe. Use caution with high doses. |
| Teratogenic Risk | First trimester: PROGESTERONE analogues are not associated with major congenital malformations; risk of hypospadias is marginally increased with high doses. Second and third trimesters: No known teratogenicity; may cause fetal and neonatal androgenization (mild virilization) with high prolonged maternal exposure. |
■ FDA Black Box Warning
Never share a Merilog SoloStar pen between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
| Serious Effects |
["Hypoglycemia","Hypersensitivity to Merilog or any of its excipients"]
| Precautions | ["Hypoglycemia is the most common adverse reaction. Monitor blood glucose closely, especially in patients with renal or hepatic impairment, and those on interacting drugs.","Medication errors: Accidental mix-ups between Merilog and other insulins have been reported. Instruct patients to check the label before each injection.","Hypersensitivity and allergic reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue if signs of allergy develop.","Peripheral edema and heart failure: Thiazolidinediones (TZDs) used in combination with insulin may cause fluid retention and heart failure. Monitor and consider dose adjustments."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal serum PROGESTERONE levels in early pregnancy for luteal phase support. Assess fetal growth and amniotic fluid index by ultrasound during prolonged therapy. Evaluate for signs of maternal thromboembolism (e.g., leg pain, chest pain). |
| Fertility Effects | No known negative impact on fertility; used to support implantation and early pregnancy. Does not impair ovarian function or sperm production. |